within Pharmacolibrary.Drugs.ATC.J;

model J05AH02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 25.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,
    adminCount     = 1,
    Vd             = 0.023399999999999997,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008616666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Oseltamivir is an antiviral medication that inhibits influenza virus neuraminidase, thereby interfering with the release of progeny influenza virus from infected host cells. It is primarily used for the treatment and prophylaxis of influenza A and B. Oseltamivir is approved for clinical use and remains a standard therapy for seasonal influenza.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects (mixed sex, ages 18-65) after single oral dose administration of oseltamivir phosphate.</p><h4>References</h4><ol><li><p>Davies, BE (2010). Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. <i>The Journal of antimicrobial chemotherapy</i> 65 Suppl 2(Suppl 2) ii5–ii10. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkq015&quot;>10.1093/jac/dkq015</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20215135/&quot;>https://pubmed.ncbi.nlm.nih.gov/20215135</a></p></li><li><p>Bardsley-Elliot, A, &amp; Noble, S (1999). Oseltamivir. <i>Drugs</i> 58(5) 851–862. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199958050-00007&quot;>10.2165/00003495-199958050-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10595865/&quot;>https://pubmed.ncbi.nlm.nih.gov/10595865</a></p></li><li><p>Baker, J, et al., &amp; Piedra, PA (2020). Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). <i>The Pediatric infectious disease journal</i> 39(8) 700–705. DOI:<a href=&quot;https://doi.org/10.1097/INF.0000000000002747&quot;>10.1097/INF.0000000000002747</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32516282/&quot;>https://pubmed.ncbi.nlm.nih.gov/32516282</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AH02;
